Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Conatus Pharmaceuticals Inc    CNAT

CONATUS PHARMACEUTICALS INC (CNAT)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 10:00:03 pm
1.52 USD   --.--%
2015MARKET SNAPSHOT : U.S. Stocks Move Lower After Mixed Jobs Report
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

CONATUS PHARMACEUTICALS INC. : Other Events (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/06/2018 | 01:33pm CET
Item 8.01 Other Events.



On December 5, 2018, Conatus Pharmaceuticals Inc. (the "Company") announced top-line results from the Company's Phase 2b ENCORE-PH clinical trial of emricasan, the Company's first-in-class, orally active pan-caspase inhibitor under development in compensated or early decompensated nonalcoholic steatohepatitis ("NASH") cirrhosis patients with severe portal hypertension. The trial's primary endpoint was change in mean hepatic venous pressure gradient (HVPG) from baseline to Week 24 in any of three emricasan dosing groups compared with placebo. The total patient population was composed of two prespecified subgroups - patients with compensated NASH cirrhosis (201 of 263 patients, or 76%) and patients with early decompensated NASH cirrhosis (62 of 263 patients, or 24%). The trial did not meet its primary endpoint in the overall trial population but clinically meaningful treatment effects were observed in subsets of the compensated patient subgroup.

In patients with compensated NASH cirrhosis, post hoc analyses demonstrated consistent improvements in mean HVPG at week 24 over baseline. The magnitude of the improvement in mean HVPG generally increased as the baseline HVPG levels increased.



            Mean HVPG Change from Baseline of Emricasan vs. Placebo*


Overall Compensated and Decompensated Patient Population Mean Baseline HVPG Emricasan 5 mg BID Emricasan 25 mg BID Emricasan 50 mg BID

     ?12 mmHg      -0.3 (p=0.666)     -0.5 (p=0.416)      -0.6 (p=0.337)
Compensated Patient Subpopulation
?12 mmHg           -1.0 (p=0.098)     -1.1 (p=0.087)      -0.7 (p=0.275)
?13 mmHg           -1.4 (p=0.047)     -1.4 (p=0.040)      -1.5 (p=0.037)
?14 mmHg           -1.5 (p=0.037)     -1.8 (p=0.015)      -1.6 (p=0.032)
?15 mmHg           -1.4 (p=0.074)     -1.6 (p=0.035)      -2.0 (p=0.017)
?16 mmHg           -2.2 (p=0.010)     -2.3 (p=0.006)      -2.0 (p=0.023)
?17 mmHg           -2.6 (p=0.009)     -2.8 (p=0.005)      -2.5 (p=0.015)



*Post-hoc analyses based on ANOVA model adjusted for baseline HVPG



            Mean HVPG Change from Baseline of Emricasan and Placebo*


Overall Compensated and Decompensated Patient Population Mean Baseline HVPG Emricasan 5 mg BID Emricasan 25 mg BID Emricasan 50 mg BID Placebo BID

     ?12 mmHg         -0.5 (N=61)         -0.7 (N=62)         -0.8 (N=56)      -0.2 (N=64)
Compensated Patient Subpopulation
?12 mmHg              -0.8 (n=46)         -0.8 (n=47)         -0.4 (n=42)      +0.2 (n=53)
?13 mmHg              -0.9 (n=39)         -0.9 (n=46)         -1.0 (n=37)      +0.5 (n=44)
?14 mmHg              -1.0 (n=35)         -1.3 (n=38)         -1.1 (n=31)      +0.5 (n=39)
?15 mmHg              -1.2 (n=30)         -1.3 (n=35)         -1.7 (n=25)      +0.3 (n=35)
?16 mmHg              -1.6 (n=26)         -1.7 (n=30)         -1.5 (n=21)      +0.5 (n=26)
?17 mmHg              -1.7 (n=23)         -1.9 (n=25)         -1.6 (n=19)      +0.9 (n=20)



*Post-hoc analyses based on ANOVA model adjusted for baseline HVPG

In a post hoc analysis, the high-risk subgroup of compensated patients with HVPG ?16 mmHg, which is the clinical cutoff to predict decompensation and higher risk of death, at baseline showed a clinically meaningful ?2-point improvement in mean HVPG compared with placebo in all three emricasan dosing groups. A trend in responses predictive of clinical benefit (?20% reduction in HVPG from baseline) was also observed in the total ?12 mmHg compensated patient population with the greatest responses observed in the ?16 mmHg cohort in the 5 mg BID and 50 mg BID dose groups.

Post Hoc ?20% Responders (from Baseline) in Compensated NASH Cirrhosis Subgroup*

Baseline HVPG Emricasan 5 mg Emricasan 25 mg BID Emricasan 50 mg BID Placebo BID

              BID
               22% (p=0.023)      13% (p=0.110)       20% (p=0.013)         0%
  ?16 mmHg       (7%, 39%)          (1%, 26%)           (6%, 42%)        (n=0/26)
                  (n=6/27)          (n=4/30)            (n=5/25)
               15% (p=0.379)      19% (p=0.162)       19% (p=0.176)         9%
  ?12 mmHg       (-7%,19%)         (-4%, 23%)          (-4%, 24%)        (n=5/53)
                  (n=7/46)          (n=9/47)            (n=8/42)



*Post-hoc chi-square test for assessing difference in response rates (95% CI of risk difference)

Consistent with safety results from 17 previously completed clinical trials, emricasan was generally well-tolerated in the ENCORE-PH clinical trial, and the overall safety profile was similar in the emricasan and placebo groups. Patients enrolled in the ENCORE-PH clinical trial are continuing treatment or placebo in a six-month extension period to evaluate longer term safety, liver function and clinical outcomes, and results from the extension are expected in mid-2019.




                                     * * *

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements, including statements regarding the timing of expected results from the six-month extension of the ENCORE-PH clinical trial. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and are subject to a number of risks, uncertainties and assumptions, including: reported top-line results are based on preliminary analysis of key data and as a result, such top-line results may change following a more comprehensive review and may not accurately reflect the complete results of the clinical trial; the Company's ability to successfully enroll patients in and complete its ongoing clinical trials; Novartis continuing development and commercialization of emricasan; the Company's reliance on third parties to conduct its clinical trials, including the enrollment of patients, and manufacture its clinical drug supplies of emricasan; potential adverse side effects or other safety risks associated with emricasan that could delay or preclude its approval; results of future clinical trials of emricasan; and those risks described in the Company's periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CONATUS PHARMACEUTICALS IN
12/06CONATUS PHARMACEUTICALS INC. : Other Events (form 8-K)
AQ
12/06CONATUS PHARMACEUTICALS INC. : Termination of a Material Definitive Agreement, U..
AQ
12/05Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirr..
GL
11/08Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual M..
GL
11/02CONATUS : 3Q Earnings Snapshot
AQ
11/01CONATUS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
11/01CONATUS PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fi..
AQ
11/01CONATUS PHARMACEUTICALS : Reports Third Quarter 2018 Financial Results and Progr..
AQ
10/25Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
GL
10/04CONATUS PHARMACEUTICALS : Announces Three Accepted Abstracts for AASLD Annual Me..
AQ
More news
Financials ($)
Sales 2018 34,9 M
EBIT 2018 -18,6 M
Net income 2018 -18,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,32x
Capi. / Sales 2019 1,10x
Capitalization 46,0 M
Chart CONATUS PHARMACEUTICALS INC
Duration : Period :
Conatus Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CONATUS PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 12,0 $
Spread / Average Target 689%
EPS Revisions
Managers
NameTitle
Steven J. Mento President, Chief Executive Officer & Director
David F. Hale Chairman
Keith W. Marshall Chief Operating & Financial Officer, Executive VP
Alfred P. Spada CSO, Executive VP-Research & Development
David T. Hagerty Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CONATUS PHARMACEUTICALS INC-67.10%46
GILEAD SCIENCES-8.47%87 125
VERTEX PHARMACEUTICALS15.72%44 319
REGENERON PHARMACEUTICALS1.39%40 244
GENMAB3.74%9 984
SAREPTA THERAPEUTICS INC114.81%8 154